{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:58:35Z","timestamp":1787029115717,"version":"build-2736575974"},"reference-count":103,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease which is associated with a 10\u201315% 5-year survival rate and poor overall prognosis. Muscle-invasive bladder cancer (MIBC) is associated with about 50% 5 year survival when treated by radical cystectomy or trimodality therapy; stage IV disease is associated with 10\u201315% 5 year survival. Current therapeutic modalities for MIBC include neoadjuvant chemotherapy, surgery and\/or chemoradiation, although patients with relapsed or refractory disease have a poor prognosis. However, the rapid success of immuno-oncology in various hematologic and solid malignancies offers new targets with tremendous therapeutic potential in UC. Historically, there were no predictive biomarkers to guide the clinical management and treatment of UC, and biomarker development was an unmet need. However, recent and ongoing clinical trials have identified several promising tumor biomarkers that have the potential to serve as predictive or prognostic tools in UC. This review provides a comprehensive summary of emerging biomarkers and molecular tumor targets including programmed death ligand 1 (PD-L1), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor (FGFR), DNA damage response and repair (DDR) mutations, poly (ADP-ribose) polymerase (PARP) expression and circulating tumor DNA (ctDNA), as well as their clinical utility in UC. We also evaluate recent advancements in precision oncology in UC, while illustrating limiting factors and challenges related to the clinical application of these biomarkers in clinical practice.<\/jats:p>","DOI":"10.3390\/molecules29081896","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T07:44:09Z","timestamp":1713771849000},"page":"1896","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4702-2017","authenticated-orcid":false,"given":"Aditya","family":"Eturi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amman","family":"Bhasin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9351-2317","authenticated-orcid":false,"given":"Kevin K.","family":"Zarrabi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5766-0195","authenticated-orcid":false,"given":"William J.","family":"Tester","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.21037\/atm.2018.05.49","article-title":"Emerging biomarkers and targeted therapies in urothelial carcinoma","volume":"6","author":"Mendiratta","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.urolonc.2016.08.019","article-title":"Circulating biomarkers to guide systemic therapy for urothelial carcinoma","volume":"Volume 34","author":"Abbosh","year":"2016","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: Efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.21037\/atm.2019.10.24","article-title":"PD-L1 assessment in urothelial carcinoma: A practical approach","volume":"7","author":"Eckstein","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Apolo, A.B., Ballman, K.V., Sonpavde, G.P., Berg, S.A., Kim, W.Y., Parikh, R.A., Teo, M.Y., Sweis, R.F., Geynisman, D.M., and Grivas, P. (2024). AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIUC) vs Observation, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e001246","DOI":"10.1136\/jitc-2020-001246","article-title":"Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis","volume":"8","author":"Apolo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2300176","DOI":"10.1200\/PO.23.00176","article-title":"Utility of tumor mutational burden as a biomarker for response to immune checkpoint inhibition in the VA population","volume":"7","author":"Scobie","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Vranic, S., and Gatalica, Z. (2023). PD-L1 testing by immunohistochemistry in immuno-oncology. Biomol. Biomed., 23.","DOI":"10.17305\/bjbms.2022.7953"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1634\/theoncologist.2019-0851","article-title":"Prognostic value of DNA damage response genomic alterations in relapsed\/advanced urothelial cancer","volume":"25","author":"Yin","year":"2020","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Geynisman, D.M., Abbosh, P., Ross, E.A., Zibelman, M.R., Ghatalia, P., Anari, F., Ansel, K., Mark, J.R., Stamatakis, L., and Hoffman-Censits, J.H. (2021). A Phase II Trial of Risk Enabled Therapy after Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN BLADDER): Interim ANALYSIS, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2021.39.6_suppl.397"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Geynisman, D.M., Abbosh, P., Ross, E.A., Zibelman, M.R., Ghatalia, P., Anari, F., Ansel, K., Mark, J.R., Stamatakis, L., and Hoffman-Censits, J.H. (2023). A Phase II Trial of Risk-Enabled Therapy after Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.6_suppl.438"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Galsky, M.D., Daneshmand, S., Chan, K.G., Dorff, T.B., Cetnar, J.P., O Neil, B., D\u2019souza, A., Mamtani, R., Kyriakopoulos, C., and Garcia, P. (2021). Phase 2 Trial of Gemcitabine, Cisplatin, Plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC): HCRN GU 16-257, Wolters Kluwer Health.","DOI":"10.1200\/JCO.2021.39.15_suppl.4503"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Galsky, M.D., Daneshmand, S., Lewis, S.C., Chan, K.G., Dorff, T.B., Cetnar, J.P., Mamtani, R., Kyriakopoulos, C., Gogerly-Moragoda, M., and Izadmehr, S. (2023). Co-Primary Endpoint Analysis of HCRN GU 16-257: Phase 2 Trial of Gemcitabine, Cisplatin, plus Nivolumab with Selective Bladder Sparing in Patients with Muscle-Invasive Bladder Cancer (MIBC), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.6_suppl.447"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1158\/0008-5472.CAN-10-1202","article-title":"MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer","volume":"70","author":"Choudhury","year":"2010","journal-title":"Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","article-title":"Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Miyamoto","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2242378","DOI":"10.1001\/jamanetworkopen.2022.42378","article-title":"Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy","volume":"5","author":"Magliocco","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: A 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sun, J.-M., Sung, J.-Y., Park, S.H., Kwon, G.Y., Jeong, B.C., Seo, S.I., Jeon, S.S., Lee, H.M., Jo, J., and Choi, H.Y. (2012). ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-187"},{"key":"ref_31","first-page":"348","article-title":"Is ERCC1 a prognostic biomarker for urothelial cancer following radical cystectomy? A long-term analysis","volume":"74","author":"Obarzanowski","year":"2021","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_32","first-page":"4899","article-title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells","volume":"62","author":"Furuta","year":"2002","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Mouw","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","article-title":"Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer","volume":"83","author":"Vis","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_37","first-page":"1265","article-title":"The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate","volume":"61","author":"Lurkin","year":"2001","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaoncol.2022.1167","article-title":"Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy","volume":"8","author":"Nimgaonkar","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Grivas, P., Daneshmand, S., Makarov, V., Bellmunt, J., Sridhar, S.S., Sonpavde, G.P., Cole, S., Tripathi, A., Faltas, B.M., and Lerner, S.P. (2023). Fibroblast Growth Factor Receptor 3 (FGFR3) Alterations in PROOF 302: A Phase III Trial of Infigratinib (BGJ398) as Adjuvant Therapy in Patients (pts) with Invasive Urothelial Carcinoma (UC), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.16_suppl.4511"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Scholtes, M.P., Alberts, A.R., Ifl\u00e9, I.G., Verhagen, P.C., van der Veldt, A.A., and Zuiverloon, T.C. (2021). Biomarker-oriented therapy in bladder and renal cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062832"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11795549221126252","DOI":"10.1177\/11795549221126252","article-title":"Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma","volume":"16","author":"Benjamin","year":"2022","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/BLC-180205","article-title":"Clinical development of FGFR3 inhibitors for the treatment of urothelial cancer","volume":"5","author":"Ibrahim","year":"2019","journal-title":"Bladder Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Loriot, Y., Matsubara, N., Park, S.H., Huddart, R.A., Burgess, E.F., Houede, N., Banek, S., Laguerre, B., Guadalupi, V., and Ku, J.H. (2023). Phase 3 THOR Study: Results of Erdafitinib (Erda) versus Chemotherapy (Chemo) in Patients (Pts) with Advanced or Metastatic Urothelial Cancer (mUC) with Select Fibroblast Growth Factor Receptor Alterations (FGFRalt), American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: Phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Weickhardt, A.J., Lau, D.K., Hodgson-Garms, M., Lavis, A., Jenkins, L.J., Vukelic, N., Ioannidis, P., Luk, I.Y., and Mariadason, J.M. (2022). Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09478-4"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.29350","article-title":"Role of ErbB\/HER family of receptor tyrosine kinases in cholangiocyte biology","volume":"67","author":"Pellat","year":"2018","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cam4.432","article-title":"HER2 as a target in invasive urothelial carcinoma","volume":"4","author":"Bellmunt","year":"2015","journal-title":"Cancer Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s12253-008-9027-y","article-title":"No strong association between HER-2\/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas","volume":"14","author":"Caner","year":"2008","journal-title":"Pathol. Oncol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy","volume":"68","author":"Crocker","year":"2008","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48905","DOI":"10.18632\/oncotarget.16554","article-title":"HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts","volume":"8","author":"Eriksson","year":"2017","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11255-007-9283-x","article-title":"Prognostic significance of Her2\/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy","volume":"40","author":"Kolla","year":"2008","journal-title":"Int. Urol. Nephrol."},{"key":"ref_58","first-page":"457","article-title":"Prognostic impact of HER2\/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years\u2019 research","volume":"14","author":"Skagias","year":"2009","journal-title":"J. BUON"},{"key":"ref_59","first-page":"7178","article-title":"Overexpression of epidermal growth factor receptor (EGFR) and HER-2 in bladder carcinoma and its association with patients\u2019 clinical features","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n, V., Rosero, D.I., Chamorro, J., Pozas, J., San Rom\u00e1n, M., Barrill, A.M., Al\u00eda, V., Sotoca, P., Guerrero, P., and Calvo, J.C. (2022). Her-2 targeted therapy in advanced urothelial cancer: From monoclonal antibodies to antibody-drug conjugates. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012659"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine+ platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Hurwitz","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/cncr.28767","article-title":"A randomized phase 2 trial of gemcitabine\/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma","volume":"120","author":"Hussain","year":"2014","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"Machiels","year":"2009","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2\u2013positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e2200165","DOI":"10.1200\/PO.22.00165","article-title":"Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2\u2013Activating Mutations: Results From the National Cancer Institute\u2013Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B","volume":"6","author":"Bedard","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2-and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody\u2013drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhou, L., Xu, H., Yan, X., Chi, Z., Cui, C., Si, L., Tang, B., Mao, L., Lian, B., and Wang, X. (2021). RC48-ADC Combined with Toripalimab, an Anti-PD-1 Monoclonal Antibody (Ab), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC): Preliminary Results of a Phase Ib\/II Study, Wolters Kluwer Health.","DOI":"10.1200\/JCO.2021.39.15_suppl.4534"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cbpa.2015.08.005","article-title":"An emerging playbook for antibody\u2013drug conjugates: Lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety","volume":"28","author":"Drake","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/CAD.0000000000000114","article-title":"Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage","volume":"25","author":"Jian","year":"2014","journal-title":"Anti-Cancer Drugs"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"869","DOI":"10.7150\/jca.65145","article-title":"Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer","volume":"13","author":"Park","year":"2022","journal-title":"J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/PAI.0000000000000124","article-title":"The prognostic and predictive significance of PARP-1 in locally advanced breast cancer of Egyptian patients receiving neoadjuvant chemotherapy","volume":"23","author":"Aiad","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2559.2012.04225.x","article-title":"High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer","volume":"61","author":"Klauschen","year":"2012","journal-title":"Histopathology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1007\/s12253-020-00856-6","article-title":"The prognostic value of PARP expression in high-grade epithelial ovarian cancer","volume":"26","author":"Beke","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.clgc.2015.12.029","article-title":"Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma","volume":"14","author":"Mullane","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.22.00405","article-title":"A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma","volume":"41","author":"Crabb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.22.00205","article-title":"Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: A multicenter, randomized, phase II trial (BAYOU)","volume":"41","author":"Rosenberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2300095","DOI":"10.1200\/PO.23.00095","article-title":"Phase II trial of olaparib in patients with metastatic urothelial cancer harboring DNA damage response gene alterations","volume":"7","author":"Doroshow","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2020.00114","article-title":"PARP inhibitors in prostate and urothelial cancers","volume":"10","author":"Garje","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"56398","DOI":"10.18632\/oncotarget.17657","article-title":"Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: A prospective study","volume":"8","author":"Soave","year":"2017","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","article-title":"Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: A pilot study","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3322\/caac.21650","article-title":"Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions","volume":"71","author":"Cheng","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ferro, M., La Civita, E., Liotti, A., Cennamo, M., Tortora, F., Buonerba, C., Crocetto, F., Lucarelli, G., Busetto, G.M., and Del Giudice, F. (2021). Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer. J. Pers. Med., 11.","DOI":"10.3390\/jpm11030237"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Li, S., Xin, K., Pan, S., Wang, Y., Zheng, J., Li, Z., Liu, X., Liu, B., Xu, Z., and Chen, X. (2023). Blood-based liquid biopsy: Insights into early detection, prediction, and treatment monitoring of bladder cancer. Cell. Mol. Biol. Lett., 28.","DOI":"10.1186\/s11658-023-00442-z"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.euo.2021.04.005","article-title":"Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: A critical review of current literature","volume":"4","author":"Green","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","article-title":"Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer","volume":"23","author":"Vandekerkhove","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1093\/annonc\/mdx405","article-title":"Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: A pilot assessment of concordance","volume":"28","author":"Barata","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.euo.2019.08.004","article-title":"Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer","volume":"4","author":"Chalfin","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/clinchem\/46.8.1078","article-title":"Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism","volume":"46","author":"Botezatu","year":"2000","journal-title":"Clin. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1538-7445.AM2019-913","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"79","author":"Christensen","year":"2019","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","article-title":"Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis","volume":"73","author":"Christensen","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Nordentoft","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","article-title":"Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma","volume":"75","author":"Sundahl","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/8\/1896\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:32:12Z","timestamp":1760106732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/8\/1896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":103,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["molecules29081896"],"URL":"https:\/\/doi.org\/10.3390\/molecules29081896","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]}}}